logo
UNIFI, Inc. Celebrates Brands Investing In Recycled Fibers

UNIFI, Inc. Celebrates Brands Investing In Recycled Fibers

Forbes11-04-2025

With more than 6.5 billion gallons of water saved and 41.4 billion megajoules of fossil fuel ... More depletion avoided, UNIFI's sustainability movement is gaining traction not just among consumers, but within entire retail supply chains.
In the sustainable fashion space, companies like U.S.-based UNIFI, Inc., the makers of recycled performance fiber
REPREVE®, continue to make strides in the circular textile manufacturing space.
Thus far, they've taken in more than 42 billion plastic bottles and turned them into recycled fiber that can be used for various consumer products. The company is on track to recycle 50 billion bottles by December 2025 and 1.5 billion t-shirts worth of textile waste by 2030.
REPREVE's growing footprint in the retail world is notable: in 2024, REPREVE accounted for 32% of UNIFI's revenue, with a target of increasing that number to more than 50% by 2030.
With more than 6.5 billion gallons of water saved and 41.4 billion megajoules of fossil fuel depletion avoided, UNIFI's sustainability movement is gaining traction not just among consumers, but within entire retail supply chains.
The retailers who use these recycled fibers in apparel, footwear, home goods, and other applications are investing in sustainability for the long term.
To celebrate its brand partners investing in recycled materials, UNIFI recently announced the winners of its 2025 Champions of Sustainability awards.
This year's honorees collectively helped divert more than 42 billion plastic bottles from landfills, simultaneously reducing greenhouse gas emissions equivalent to 1.3 billion kilograms of carbon dioxide.
The eighth annual awards spotlighted brands driving sustainable innovation across the retail and textile industries. Key partners such as Nike, Target, Walmart, and Polartec received the Billion Bottle Award for recycling over one billion bottles through their supply chains.
Newcomers like Free Country and Swannies were celebrated for surpassing the 10 million bottle milestone, while New Balance and Signet Mills were honored for their commitment to domestic manufacturing.
'Mainstreaming sustainable and circular solutions requires collaboration across industries, supply chains, R&D, and technology,' said Eddie Ingle, CEO of UNIFI. 'This year's REPREVE Champions of Sustainability are pushing boundaries and setting new benchmarks for environmental responsibility.'
Zooming out, it's clear there are still many more opportunities for expanding investment in recycled materials. The 2024 Circularity Gap Report (Textiles) found that only 0.3% of the 3.25 billion tons of resources consumed each year to produce items within the global textile industry come from recycled resources.
Operators like Ali Rose van Overbeke, who currently serves as the Director of Marketing at Kadeya but previously founded Genusee, a company that formerly specialized in manufacturing eyeglasses made from recycled plastic bottles, know how challenging this path can be.
She explained that because recycling is a for-profit industry, it's subject to the same market forces as any other: supply and demand, margins, and the need to optimize for return on investment.
'In the best-case scenario, materials are collected, cleaned, sorted, and baled. Those bales are sold to processors, who mechanically or chemically break them down into pellets, flakes, or fibers. Those then get sold to companies to be turned into final goods—like fabric, eyewear, or packaging,' she said.
However, she went on to explain that if brands aren't buying those recycled materials, processors won't buy from recyclers, and recyclers have no incentive to collect or sort them in the first place. The entire system has to work together, collectively, toward the end goal of increased sustainability.
For UNIFI, with its more than 3.1 million square feet of manufacturing and sorting facilities based in North Carolina as well as direct operations in Colombia, El Salvador, and Brazil, the infrastructure for apparel brands committed to investing in sustainable materials presents an opportunity for brands to invest in more responsible production in 2025 and beyond.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Business Wire

timean hour ago

  • Business Wire

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit

EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI
EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI

Yahoo

time2 hours ago

  • Yahoo

EthicAI Advisory Limited: Cambridge spinout launches new tool to boost confidence in AI

LONDON, June 9, 2025 /PRNewswire/ -- EthicAI Advisory Limited ("EthicAI"), a University of Cambridge spinout and global leader in the ethical and responsible assurance of artificial intelligence, has launched a cloud-based AI assurance SaaS platform to address ethical and trust issues around the adoption of AI, unlocking the technology's economic potential. AI models can create problems across a number of areas: Fairness and bias — AI systems can discriminate against certain groups including through hidden bias in training data Transparency — automating workflows can create 'black box' issues where algorithmic decision-making is opaque and consequently hard to understand and challenge Employee impacts — automation may unintentionally disempower, not augment, human workers if not designed carefully. The adoption of AI without enablement and literacy programmes can also erode company culture and employee motivation BeehAIve® scrutinises models and datasets against 15 ethical dimensions, assessing evidence across thousands of measurement points. The platform allows organisations to design, deploy and monitor autonomous systems that are optimised for success. BeehAIve® allows for technical stress-testing of model performance to improve reliability, robustness and security, while also recommending ways to reduce energy usage from AI. The platform enables assessment of models and systems against regional and national legislation including the EU AI Act, GDPR, the Korean AI Act, as well as industry-specific regulations and globally recognised AI standards. BeehAIve® then recommends how gaps can be filled, preparing for cross-border compliance while building stakeholder trust. The platform offers organisations a secure hub for their AI data, ensuring information remains safe and encrypted at all times. Tanya Goodin, Founder & CEO of EthicAI says: "BeehAIve® is a unique platform that enables organisations and their stakeholders to adopt AI with increased trust and confidence. Research shows that consumer confidence in AI has fallen by 8% globally over the past five years due to concerns about how AI is designed and built. BeehAIve® looks under the hood of organisations' AI models and systems — both in development and post deployment — to identify blind spots and weaknesses and provides actionable insights on how to mitigate and manage risks." For further information, contact: tanya@ or tim@ EthicAI Advisory Ltd EthicAI was formed in 2022 to build trust in AI by assuring models and systems to the highest ethical and responsible standards. EthicAI spun out of the University of Cambridge's Leverhulme Centre for the Future of Intelligence, with all the founding team previously engaged in cutting-edge AI ethics research at the university. The founders' leadership experience spans organisations including the BBC, Fidelity Investments, Barclays, Merrill Lynch, Deutsche Bank and UBS. Read more about the team here. EthicAI's cloud-based platform BeehAIve® will allow the company to scale its offer, and bring solutions to more organisations, more rapidly. It sits at the heart of the company's mission to ensure the ethical and responsible adoption of state-of-the-art AI systems — powering their success and helping to strengthen the UK's position as a leader in artificial intelligence. View original content: Sign in to access your portfolio

Jim Cramer Says He 'Personally Would Not Own Altria (MO)'
Jim Cramer Says He 'Personally Would Not Own Altria (MO)'

Yahoo

time6 hours ago

  • Yahoo

Jim Cramer Says He 'Personally Would Not Own Altria (MO)'

We recently published a list of . In this article, we are going to take a look at where Altria Group, Inc. (NYSE:MO) stands against other stocks that Jim Cramer discusses. Answering a caller's query about Altria Group, Inc. (NYSE:MO), Cramer commented: 'Alright, but here's, okay, so I'm going to give you two answers to this because I've been trying to change my mind about some things…. I personally would not own Altria. Why? Because I don't like what they do. Is it a superior stock better than most? The answer is, as I was writing How to Make Money in Any Market, the answer is yes. So you've got two answers. It's up to you. I couldn't own it for my trust. I couldn't live with myself.' A close-up of an assembly line with a blend of tobacco products. Altria (NYSE:MO) produces and markets a range of tobacco and nicotine products, including cigarettes, cigars, smokeless tobacco, nicotine pouches, and e-vapor devices, sold under brands like Marlboro, Black & Mild, Copenhagen, and NJOY ACE. Andvari Associates stated the following regarding Altria Group, Inc. (NYSE:MO) in its Q1 2025 investor letter: 'Last year, Andvari made its first investments in tobacco companies with the purchase of Philip Morris International and Altria Group, Inc. (NYSE:MO). At the time of our purchase, Philip Morris and Altria had underperformed the S&P 500 over the prior 5- and 10-year periods. Both traded at low valuations and with high dividend yields. But thanks to following the industry o and on for 10+ years, and thanks to many discussions with long-time shareholders of the companies, Andvari felt the time was right to make the plunge. The timing could not have been much better for us as both companies have so far contributed positively to Andvari's recent overall performance. Overall, MO ranks 8th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of MO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store